Merit Medical Launches Resilience TTS Esophageal Stent in Three Sizes with Anti-Migration Flanges
Merit Medical Systems commercially released the Resilience Through-the-Scope Esophageal Stent in the US, featuring proprietary anti-migration flanges and a single-handed deployment system. It is offered in three unique sizes—14×50 mm, 17×50 mm and 20×50 mm—to treat esophageal fistulas and malignant strictures in a market facing high cancer-related mortality.
1. Product Launch and Key Features
Merit Medical introduced the Resilience Through-the-Scope Esophageal Stent in US markets, integrating proprietary anti-migration flanges to anchor the device and a single-handed deployment system for precise placement.
2. Clinical Indications and Design Advantages
The stent is indicated for esophageal fistulas and strictures caused by malignant tumors, offering what the company claims is the greatest migration resistance among available TTS stents.
3. Market Potential and Strategic Impact
This launch expands Merit’s Endoscopy portfolio into a segment where esophageal cancer ranks sixth in global mortality, positioning the company to capture share in a rapidly growing TTS stent market.
4. Company Profile
Founded in 1987, Merit Medical Systems develops and distributes proprietary devices for interventional, diagnostic and therapeutic procedures, employing roughly 7,600 people and supported by an 800-member global sales and clinical team.